In addition, phase I clinical trials conducted in patients with non-small cell lung cancer (NSCLC) or lymphoid malignancies [32,33] have shown that navitoclax is safe and well tolerated; however a dose-dependent thrombocytopenia, a consequence of BCL-XL inhibition [34], was a major adverse effect. This evidence concerns the gene BCL2L1 and Thrombocytopenia.